Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer

PURPOSE: Phosphatidylinositol 3-kinase (PI3K) inhibitors are being developed for the treatment of estrogen receptor α (ER)-positive breast cancer in combination with anti-estrogens. Understanding the temporal response and pharmacodynamic effects of PI3K inhibition in ER+ breast cancer will provide r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Yang, Wei, Hosford, Sarah R., Dillon, Lloye M., Shee, Kevin, Liu, Stephanie C., Bean, Jennifer R., Salphati, Laurent, Pang, Jodie, Zhang, Xiaolin, Nannini, Michelle A., Demidenko, Eugene, Bates, Darcy, Lewis, Lionel D., Marotti, Jonathan D., Eastman, Alan R., Miller, Todd W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2016
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854767/
https://ncbi.nlm.nih.gov/pubmed/26733612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2276
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller